Suven Life Sciences Ltd (SUVEN) — shareholding pattern, promoter holding, financials and share price
About Suven Life Sciences Ltd (SUVEN)
Suven Life Sciences Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as SUVEN and on the BSE under scrip code 530239. Its ISIN is INE495B01038.
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. [1]
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company primarily focused on developing novel therapeutics for neurodegenerative disorders. Its operations include Contract Research And Manufacturing Services (CRAMS), offering process research, clinical trial supplies, and exclusive manufacturing services.
The company has expanded its drug discovery into areas such as Major Depressive Disorder, pain management, and obesity, showcasing its specialization in CNS-based programmes.
Listed peers in Healthcare Research, Analytics & Technology: Syngene International Ltd, Indegene Ltd, Vimta Labs Ltd, Take Solutions Ltd, Bilcare Ltd, Jeevan Scientific Technology Ltd.
Valuation & Returns
10 Jul 2026At ₹360 a share on 10 Jul 2026, Suven Life Sciences Ltd (SUVEN) was valued at a price-to-earnings ratio of -36.63x against an industry P/E of 61.73x and a price-to-book of 92.49x on a book value of ₹3.89 per share as of Mar 2025. Solomo computes return on equity of -251.26% and return on capital employed of -251.11% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -36.63x
- Industry P/E
- 61.73x
- P/B
- 92.49x
- EPS (TTM)
- ₹-9.78
- Book value / share
- ₹3.89
- ROE
- -251.26%
- ROCE
- -251.11%
- ROA
- -204.43%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹124.35 – ₹370.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Suven Life Sciences Ltd (SUVEN) reported revenue of ₹7 crore, net profit of ₹-276 crore and earnings per share of ₹-10.48. That compares with revenue of ₹7 crore and net profit of ₹-161 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2 crore and net profit ₹-46 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 12 | 14 | 12 | 7 | 7 |
| Net profit (₹ cr) | -122 | -118 | -105 | -161 | -276 |
| EPS (₹) | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -38.12% | -14.32% | -17.48% | -43.03% |
| Profit growth | - | - | - | -52.98% |
| Stock price CAGR | 39% | 32% | 76% | 16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 70.08% of Suven Life Sciences Ltd (SUVEN) (down 0.07 pp QoQ), foreign institutional investors (FII) hold 0.57% and domestic institutional investors (DII) hold 2.93%. Market capitalisation was ₹10,172 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: 3P INDIA EQUITY FUND 1 1.27%, ABAKKUS DIVERSIFIED ALPHA FUND 1.07%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 70.08% | - | 0.57% | 2.93% | 29.92% |
| Mar 2026 | 70.15% | - | 0.91% | 4.62% | 29.85% |
| Dec 2025 | 67.36% | - | 1.07% | 3.39% | 32.64% |
| Sep 2025 | 67.36% | - | 1.18% | 3.39% | 32.64% |
| Jun 2025 | 70.27% | - | 0.59% | 0.02% | 29.73% |
| Mar 2025 | 70.27% | - | 0.25% | 0.01% | 29.73% |
| Dec 2024 | 70.27% | - | 0.34% | 1.06% | 29.73% |
| Sep 2024 | 70.27% | - | 0.34% | 1.05% | 29.73% |